NCT05073809

Brief Summary

Cancer is the commonest cause of death in the UK, and a national and international healthcare priority. Survival in the UK is relatively poor vs. European comparators1, meaning early tumour detection and accurate clinical assessment is particularly important to improve outcomes. Treatment fundamentally depends on tumour staging, both of the local cancer and of draining lymph nodes (LN), as well as distant spread of disease i.e. TNM stage (tumour (T), node (N) and metastases (M). However, current non-invasive pre-operative imaging technologies of ultrasound (US), computed tomography (CT) and magnetic resonance imaging (MRI) are limited in sensitivity and specificity for nodal assessment, either missing disease or subjecting patients to unnecessary additional invasive biopsies or surgery. A simple, rapid, non-invasive tool to assess primary tumours and LN involvement would be of great clinical value. One candidate technology is photoacoustic tomography (PAT), a relatively novel modality that combines exquisite spatial resolution with the ability to image multiple biological tissues, including blood, water and lipid. To date, PAT has been most successful in imaging the vasculature, which is of particular interest for oncological imaging because one of the key hallmarks of cancer is the development of new, abnormal blood vessels (neoangiogenesis). The high sensitivity for superficial imaging with PAT means that head and neck tumours and neck LN are readily amenable for assessment. In this cohort of patients, those with oral cavity tumours, in particular tumours arising from the lining of the tongue, would be readily accessible for direct scanning.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2022

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 15, 2020

Completed
12 months until next milestone

First Posted

Study publicly available on registry

October 12, 2021

Completed
12 months until next milestone

Study Start

First participant enrolled

September 29, 2022

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 29, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 29, 2022

Completed
Last Updated

October 27, 2023

Status Verified

October 1, 2023

Enrollment Period

Same day

First QC Date

October 15, 2020

Last Update Submit

October 24, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Group 2

    the primary outcome is to identify the proportion of participants with oral cavity cancer in whom DOI can be successfully measured with PAT i.e. technical success. The outcome is to measure the success of the photoacoustic scanner.

    3 years

Study Arms (2)

Group 1

Proven or highly suspected head and neck tumour undergoing routine clinical staging of their neck LN status

Diagnostic Test: Photoacoustic Imaging Scan

Group 2

Proven or suspected oral cavity cancer, amenable to intraoral examination

Diagnostic Test: Photoacoustic Imaging Scan

Interventions

A relatively novel modality that combines exquisite spatial resolution with the ability to image multiple biological tissues, including blood, water and lipid.

Group 1Group 2

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Head and neck tumours

You may qualify if:

  • Proven or highly suspected to have a head and neck tumour, including oral cavity cancer, and/or abnormal LN in the head and neck (on the basis of physical examination or medical imaging).
  • years or older (no upper age limit).

You may not qualify if:

  • Unable to provide informed written informed consent (e.g. dementia, significant mental illness, brain metastases).
  • Severe skin or mucosal disease precluding safe, comfortable placement of the US or PAT probes (e.g. active infection; ulcerating tumour).
  • Contraindication to MRI magnetic field e.g. non-MRI compatible pacemaker, cochlear implant, severe claustrophobia, or allergy to MRI contrast agent (Gadolinium)
  • Restricted mouth opening in those patients with an oral cavity neoplasm

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (3)

  • Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R; EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009 Apr;45(6):931-91. doi: 10.1016/j.ejca.2008.11.018. Epub 2009 Jan 24.

    PMID: 19171476BACKGROUND
  • Abu-Ghanem S, Yehuda M, Carmel NN, Leshno M, Abergel A, Gutfeld O, Fliss DM. Elective Neck Dissection vs Observation in Early-Stage Squamous Cell Carcinoma of the Oral Tongue With No Clinically Apparent Lymph Node Metastasis in the Neck: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2016 Sep 1;142(9):857-65. doi: 10.1001/jamaoto.2016.1281.

    PMID: 27442962BACKGROUND
  • Mizrachi A, Migliacci JC, Montero PH, McBride S, Shah JP, Patel SG, Ganly I. Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution. Oral Oncol. 2018 Mar;78:94-101. doi: 10.1016/j.oraloncology.2018.01.020. Epub 2018 Feb 20.

    PMID: 29496065BACKGROUND

MeSH Terms

Conditions

Head and Neck Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasms
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 15, 2020

First Posted

October 12, 2021

Study Start

September 29, 2022

Primary Completion

September 29, 2022

Study Completion

September 29, 2022

Last Updated

October 27, 2023

Record last verified: 2023-10